Avacta, with the help of the FDA, in their announcement of a single pivotal trial, dramatically increases the rNPV of AVA6000, by reducing execution uncertainly and regulatory risk!
Immense intrinsic value has been created and will. Congratulations to the team #AVCT
A number of exceptional headlines coming out of @avacta#AVCT today.
The fact that one is titled ‘Platform-Validating’ tells you everything about management confidence in the company.
~25% increase required to get back to 52 week highs and it’ll come but I’m super relaxed.
A few weeks ago, in an interview with Venture Road, @coughlin582 said that “the next data coming out in a few weeks, we believe that this dataset is really going to be validating for the platform”
The referenced data will drop sometime this week. Exciting times @avacta#AVCT
Today’s news further validates and most importantly de-risks the entire pre|CISION platform. Share price should continue with its appreciation and rerate massively over the coming weeks/months!
Looking forward to the presentation at 10am #AVCT
We’re right on the edge of a potential value inflection point:
Strong science, improving clinical results, regulatory opportunity - all converging.
SGC data is close. The market is pricing in near 0% success.
I’m excited. Watching daily.
#AVCT 🚀🔥
We’re now at the point where new SGC (Salivary Gland Cancer) data from @avacta could land any day and honestly this might be one of the most important updates in the company’s history.
Here’s why I’m genuinely excited👇
Of course, more patients and longer follow ups are needed.
Phase 1 isn’t the finish line.
But if the new SGC data confirms tumour shrinkage + safety + consistency, the risk/reward profile for Avacta shifts dramatically.
@avacta closing at yearly highs after healthy pull back. So much to look forward to as our next trading day takes us into December, a month of 🧨 and 🚀’s!
Triple digit share price coming sooner rather than later ⏳
#AVCT
US Biotech S&P ETF breaking out to new highs. Lot’s of money flow into the sector with big names stating M&A opportunities being looked at. Bode’s well and coincides with @avacta’s announcement of P1b data due this qtr.
Partnership and/or deals announced post data IMO #AVCT
Credit to Zeus & Hughes. All placing shares look like they’ve gone into the stickiest of hands and this bodes well as we’ve now entered explosive territory 💣 Q4/Q1(26).
Criminally undervalued & looks like we’ll be seeing incremental gains over the coming weeks #AVCT
CC “there are partners waiting for small bits of additional data”…
��Avacta expects to release Phase 1b data for the TNBC and soft tissue sarcoma cohorts at the end of 2025’
<8 weeks to go 🤞🏼 #AVCT